Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 15OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 267Triple Negative Breast Neoplasms 18Neoplasms 9Lymphedema 9Motor Activity 8Breast Cancer Lymphedema 8Breast Cancer Female 8Pathologic Complete Response 6Neoplasm Metastasis 6Colorectal Neoplasms 6Colonic Neoplasms 6Pain 5Fatigue 5Stomach Neoplasms 4Pain, Postoperative 4Recurrence 3Radiodermatitis 3Hereditary Breast and Ovarian Cancer Syndrome 3Endometrial Neoplasms 3Drug-Related Side Effects and Adverse Reactions 3Breast Diseases 3Advanced Breast Cancer 3Treatment Adherence and Compliance 2Thyroid Neoplasms 2Seroma 2Radiation Injuries 2Ovarian Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Breast Cancer Invasive × Breast × Clear all
NCT06781281 2025-06-23

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Henan Cancer Hospital

Recruiting
709 enrolled
Breast

Breast Cancer Invasive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡